Men and women may be affected differently by retinitis pigmentosa, a disease that causes blindness over time. That's ...

Aldeyra Therapeutics received FDA fast track designation for ADX-2191 for the treatment of retinitis pigmentosa, according to ...

Presentation title : Subretinal gene therapy laru-zova for X-linked retinitis pigmentosa (XLRP): Phase 2 DAWN trial, preliminary month 9+ results Date : Thursday, September 4, 2025 Presenter : Rajiv ...

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for ADX-2191 (methotrexate intravitreal ...

ADX-2191 is a preservative-free intravitreal formulation of methotrexate designed to treat various rare retinal diseases such as retinitis pigmentosa.

NEWPORT BEACH, Calif., August 18, 2025--jCyte, Inc. is pleased to announce the first patients have been enrolled and treated ...

Cyte initiates patient dosing in a new trial for famzeretcel, aiming to transform treatment options for retinitis pigmentosa.

In this Healio Video Perspective from the Retina World Congress, Huma Qamar, MD, MPH, of Ocugen, overviews programs for ...

WILMINGTON, DE, UNITED STATES, August 21, 2025 /EINPresswire.com/ -- The global pigments market is witnessing significant ...

With this milestone, VG801 now holds RMAT, Rare Pediatric Disease, and Orphan Drug designations. VeonGen has also been selected to collaborate with the FDA under the Rare Disease Endpoint Advancement ...

Emma Nicoson and Aaron See, who has retinitis pigmentosa, want to make fashion websites more accessible for people with ...